Soleno Therapeutics Net Worth

Soleno Therapeutics Net Worth Breakdown

  SLNO
The net worth of Soleno Therapeutics is the difference between its total assets and liabilities. Soleno Therapeutics' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Soleno Therapeutics' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Soleno Therapeutics' net worth can be used as a measure of its financial health and stability which can help investors to decide if Soleno Therapeutics is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Soleno Therapeutics stock.

Soleno Therapeutics Net Worth Analysis

Soleno Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Soleno Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Soleno Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Soleno Therapeutics' net worth analysis. One common approach is to calculate Soleno Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Soleno Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Soleno Therapeutics' net worth. This approach calculates the present value of Soleno Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Soleno Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Soleno Therapeutics' net worth. This involves comparing Soleno Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Soleno Therapeutics' net worth relative to its peers.
To determine if Soleno Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Soleno Therapeutics' net worth research are outlined below:
Soleno Therapeutics generated a negative expected return over the last 90 days
Soleno Therapeutics has high historical volatility and very poor performance
Soleno Therapeutics has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (38.99 M) with profit before overhead, payroll, taxes, and interest of 0.
Soleno Therapeutics currently holds about 24.07 M in cash with (24.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.97.
Over 97.0% of the company shares are owned by institutional investors
Soleno Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Soleno Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Soleno Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
19th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
19th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Follow Soleno Therapeutics' market capitalization trends

The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.15 B.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Soleno Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Soleno Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Soleno Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
James MacKaness over a week ago
Acquisition by James MacKaness of 14500 shares of Soleno Therapeutics subject to Rule 16b-3
 
Anish Bhatnagar over a week ago
Acquisition by Anish Bhatnagar of 115600 shares of Soleno Therapeutics at 49.17 subject to Rule 16b-3
 
Vivo Opportunity, Llc over a week ago
Disposition of 500000 shares by Vivo Opportunity, Llc of Soleno Therapeutics at 48.73 subject to Rule 16b-3
 
Anish Bhatnagar over three weeks ago
Disposition of 10154 shares by Anish Bhatnagar of Soleno Therapeutics at 46.1764 subject to Rule 16b-3
 
Anish Bhatnagar over three months ago
Acquisition by Anish Bhatnagar of 100000 shares of Soleno Therapeutics at 36.7 subject to Rule 16b-3
 
Patricia Hirano over three months ago
Disposition of 1359 shares by Patricia Hirano of Soleno Therapeutics at 36.4853 subject to Rule 16b-3
 
Patricia Hirano over three months ago
Disposition of 888 shares by Patricia Hirano of Soleno Therapeutics at 41.6671 subject to Rule 16b-3
 
Yen Kristen over three months ago
Disposition of 7 shares by Yen Kristen of Soleno Therapeutics at 48.3 subject to Rule 16b-3
 
Vivo Opportunity, Llc over three months ago
Disposition of 100000 shares by Vivo Opportunity, Llc of Soleno Therapeutics at 47.22 subject to Rule 16b-3
 
Yen Kristen over three months ago
Disposition of 16284 shares by Yen Kristen of Soleno Therapeutics at 37.0245 subject to Rule 16b-3
 
Urbanski Raymond W. over three months ago
Insider Trading
 
Anish Bhatnagar over three months ago
Disposition of 405 shares by Anish Bhatnagar of Soleno Therapeutics at 45.89 subject to Rule 16b-3
Soleno Therapeutics time-series forecasting models is one of many Soleno Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Soleno Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Soleno Therapeutics Earnings per Share Projection vs Actual

Soleno Therapeutics Corporate Management

Kristen MSSenior OperationsProfile
Dr MBASenior DevelopmentProfile
Patricia MPHSenior AffairsProfile
PharmD MBASenior AffairsProfile
Meredith MBAChief OfficerProfile
Anish MDCEO and PresidentProfile
When determining whether Soleno Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Soleno Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Soleno Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Soleno Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.
To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Medical Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.